Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook
Key Takeaways from the Ulcerative Colitis Pipeline Report
In April 2025, Merck Sharp & Dohme LLC announced a study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.
In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment
Ulcerative Colitis Emerging Drugs Profile
Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.
ABBV-668: AbbVie
ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
TEV-48574: Teva Pharmaceutical
Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
SOR102: Sorriso Pharmaceuticals
SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.
The Ulcerative Colitis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market
Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs
Ulcerative Colitis Companies
Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Ulcerative Colitis Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives
Scope of the Ulcerative Colitis Pipeline Report
Coverage- Global
Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
"Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies
Table of Content
Introduction
Executive Summary
Ulcerative Colitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ulcerative Colitis– DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis Collaboration Deals
Late Stage Products (Preregistration)
Mirikizumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Obefazimod: Abivax
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-668: AbbVie
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SOR102: Sorriso Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 days ago
- Globe and Mail
Oncocytoma Market Poised for Growth Through 2032, Fueled by AI Diagnostics and Minimally Invasive Surgery
The Oncocytoma market is experiencing notable growth, with the 7MM projected to achieve a decent CAGR, according to DelveInsight's latest analysis. This growth reflects advancements in molecular diagnostics and minimally invasive surgical technologies that are reshaping treatment paradigms for this rare renal and salivary gland tumor. DelveInsight's report, ' Oncocytoma - Market Insight, Epidemiology And Market Forecast - 2032 ', provides a comprehensive assessment of oncocytoma market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the oncocytoma market size in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase notably over the coming years. This growth is primarily driven by the increased adoption of non-invasive treatment options and advancements in early detection technologies. The United States represents the largest share of the oncocytoma market. The EU4 countries and the United Kingdom collectively make up the second-largest market share. Download the oncocytoma market report to understand which factors are driving the oncocytoma therapeutic market @ Oncocytoma Market Trends. The epidemiological data presented in the report indicate key trends in incidence, demographics, and the oncocytoma patient pool. The data reveal a steadily expanding oncocytoma patient pool across the 7MM, with the median age at diagnosis for renal oncocytoma typically ranging from 62 to 68 years. Additionally, it has also been indicated that oncocytomas predominantly affect males across the studied regions. The report also explores the current and evolving Oncocytoma treatment landscape. As of now, there are no FDA-approved drugs specifically targeting oncocytoma. Instead, oncocytomas are typically managed through surgical excision (such as partial or radical nephrectomy) or minimally invasive techniques like cryoablation or radiofrequency ablation when necessary. While surgical intervention remains the cornerstone of current management, there is an accelerated innovation in diagnostic accuracy and the differentiation of these tumors from malignant renal counterparts. Recently, AI-driven diagnostic tools have been integrated into clinical practice, showing promising results in the diagnosis and preoperative planning for oncocytoma. One study revealed that an AI system achieved over 90% accuracy in distinguishing clear cell renal cell carcinoma (RCC) from oncocytoma using MRI scans. Additionally, a comparative analysis indicated that the AI model outperformed radiologists in distinguishing benign tumors, such as oncocytoma and angiomyolipoma, from RCC subtypes. This highlights the potential of AI to reduce diagnostic ambiguity within the oncocytoma treatment landscape. Discover evolving trends in the oncocytoma treatment landscape @ Oncocytoma Therapeutics Market. Looking ahead, the oncocytoma market is set for significant growth, driven by advancements in diagnostic technologies and surgical techniques. Despite challenges posed by the benign nature of these tumors, which can lead to misdiagnosis and potential overtreatment, the field is witnessing a paradigm shift. The integration of artificial intelligence in imaging and the development of molecular diagnostic tools are enhancing the accuracy of preoperative diagnosis, reshaping patient management strategies As research continues to uncover the molecular intricacies of oncocytomas, the market is expected to expand, offering more personalized treatment options and improved long-term monitoring techniques to address the unmet needs in this landscape. Unlock which oncocytoma drug is expected to capture the largest market share in 7MM by 2032. Visit the Oncocytoma Market Insights. Table of Contents 1. Key Insights 2. Executive Summary of Oncocytoma 3. Oncocytoma Competitive Intelligence Analysis 4. Oncocytoma: Market Overview at a Glance 5. Oncocytoma: Disease Background and Overview 6. Oncocytoma Patient Journey 7. Oncocytoma Epidemiology and Patient Population 8. Oncocytoma Treatment Algorithm, Current Treatment, and Medical Practices 9. Oncocytoma Unmet Needs 10. Key Endpoints of Oncocytoma Treatment 11. Oncocytoma Marketed Products 12. Oncocytoma Emerging Therapies 13. Oncocytoma: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Oncocytoma Access and Reimbursement Overview 17. KOL Views 18. Oncocytoma Market Drivers 19. Oncocytoma Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Oncocytoma Pipeline Insight Oncocytoma Pipeline Insight provides comprehensive insights about the oncocytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the oncocytoma companies. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Globe and Mail
3 days ago
- Globe and Mail
Ulcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline
The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others. DelveInsight's " Ulcerative Colitis Market Insight, Epidemiology And Market Forecast - 2034" report delivers comprehensive insights into the ulcerative colitis market dynamics, epidemiological trends, and treatment landscape across the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The ulcerative colitis market size in the 7MM was USD 8.4 billion in 2023, with the United States accounting for the largest share at USD 5.9 billion. This market is poised for significant growth during the forecast period (2024-2034), driven by improved drug uptake, increased disease awareness, and a robust pipeline of innovative therapies. Download the Ulcerative Colitis market report to understand which factors are driving the Ulcerative Colitis therapeutic market @ Ulcerative Colitis Market Trends. The report also provides a detailed epidemiological analysis and forecasts up to 2034, segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis. According to the latest epidemiological analysis, the total diagnosed prevalent cases of ulcerative colitis in the 7MM comprised approximately 3 Million in 2023, with projections indicating continued growth through 2034. The United States contributed the largest share, with approximately 47% of the diagnosed prevalent population, while Germany and Japan each accounted for roughly 10% of the total 7MM patient pool. When examining disease severity, approximately 521K mild cases and 860K moderate to severe cases were identified across these markets. Discover evolving trends in Ulcerative Colitis patient pool forecasts @ Ulcerative Colitis Epidemiology Analysis. The ulcerative colitis treatment market currently encompasses multiple therapeutic approaches, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, S1P modulators, and Janus kinase inhibitors. Anti-TNF alpha agents remain the recommended first-line treatment option for many patients. Among the currently approved therapies, HUMIRA (AbbVie), REMICADE (Janssen Pharmaceuticals), SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), XELJANZ (Pfizer), STELARA (Janssen Pharmaceuticals), CAROGRA (EA Pharma/Kissei Pharma), JYSELECA (Gilead Sciences and Galapagos NV), OMVOH (Eli Lilly), SKYRIZI (AbbVie/Boehringer Ingelheim), RINVOQ (AbbVie), and ZEPOSIA (Bristol-Myers Squibb), among others have established strong market positions. By 2034, ENTYVIO is projected to generate the highest revenue in the United States, followed by HUMIRA (AbbVie). In December 2024, Biocon Biologics and Celltrion received FDA approval for their respective biosimilars to STELARA (Janssen Pharmaceuticals) – YESINTEK (Biocon Biologics) and STEQEYMA (Celltrion) – expanding treatment options for patients with ulcerative colitis. In February 2024, the European Commission granted marketing authorization for VELSIPITY (etrasimod) for patients 16 years and older with moderately to severely active ulcerative colitis following its FDA approval in October 2023. The ulcerative colitis therapeutics market is witnessing significant innovation with several emerging therapies such as, Etrasimod (Arena Pharmaceuticals/Pfizer), ABX464 (Abivax), SHR0302 (Reistone Biopharma), Cobitolimod (InDex Pharmaceuticals), TREMFYA (Janssen Pharmaceuticals), BT-11 (Landos Biopharma/NImmune), PRA023 (Merck), Remestemcel-L (Mesoblast), PF-06651600 (Pfizer) and PF-06700841 (Pfizer) among others. Know which Ulcerative Colitis drug is expected to capture the largest market share in 7MM by 2034. Visit the Ulcerative Colitis Insights. Recent developments have further enriched the ulcerative colitis market with several regulatory approvals and clinical advancements. In December 2024, Accropeutics Inc. announced FDA clearance for a Phase II trial of its RIPK2 inhibitor, AC-101, for moderate-to-severe Ulcerative Colitis. Additionally, in November 2024, Johnson & Johnson submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of TREMFYA (guselkumab). In late 2024, AbbVie's SKYRIZI had rapidly outpaced Eli Lilly's OMVOH in the ulcerative colitis market, securing over double the market share just two months post-launch. In January 2025, the FDA granted investigational new drug (IND) clearance for R-5780 (Rise Therapeutics). This innovative therapy leverages gut-regulated immune pathways to enhance the efficacy of immune checkpoint inhibitors, offering a novel approach to treating cancers that are refractory or unresponsive to these therapies. Looking ahead, the ulcerative colitis market is expected to witness significant transformation with the introduction of novel therapeutic classes, including toll-like receptor 9 activators, miR-124 enhancers, and T-cell therapies. While high therapy costs and complications pose challenges, rising awareness, early screening, and advanced treatment strategies are fueling ulcerative colitis treatment market growth. The ulcerative colitis epidemiology and the market landscape present both opportunities and challenges for stakeholders. As treatment paradigms continue to evolve, focusing on personalized medicine and improved patient outcomes, the ulcerative colitis treatment market is positioned for substantial growth, offering new hope for the millions affected by this chronic inflammatory condition worldwide. Table of Contents 1. Key Insights 2. Report Introduction 3. Ulcerative Colitis Market Overview at a Glance 4. Epidemiology and Market Methodology 5. Ulcerative Colitis Executive Summary 6. Ulcerative Colitis Market Disease Background and Overview 7. Ulcerative Colitis Epidemiology and Patient Population 8. Patient Journey 9. Ulcerative Colitis Marketed Therapies 10. Ulcerative Colitis Emerging Drugs 11. Ulcerative Colitis: The 7MM Analysis 12. Ulcerative Colitis Market Access and Reimbursement 13. Ulcerative Colitis KOL Views 14. Ulcerative Colitis SWOT Analysis 15. Ulcerative Colitis Unmet Needs 16. Appendix 17. DelveInsight Capabilities 18. Disclaimer Related Reports Ulcerative Colitis Pipeline Insight Ulcerative Colitis Pipeline Insight provides comprehensive insights about the Ulcerative Colitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ulcerative Colitis manufacturers, including Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, and Palatin Technologies, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
4 days ago
- Globe and Mail
ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report Key Takeaways from the ESCLC Pipeline Report In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer. In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS). In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327. DelveInsight's ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment. The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others. Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!" @ ESCLC Clinical Trials Assessment ESCLC Emerging Drugs Profile Serplulimab+Chemo: Shanghai Henlius Biotech Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). RYZ101: RayzeBio, Inc. RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC). The ESCLC Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment. ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market. From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! @ ESCLC Treatment Drugs ESCLC Companies Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ESCLC Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Stay updated with the latest ESCLC Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives Scope of the ESCLC Pipeline Report Coverage- Global ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others. ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others. ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ ESCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Extensive Stage Small Cell Lung Cancer (ESCLC): Overview Pipeline Therapeutics Therapeutic Assessment Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Serplulimab+Chemo: Shanghai Henlius Biotech Mid-Stage Products (Phase II) Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Early Stage Products (Phase I) RYZ101: RayzeBio, Inc. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
